2025– date –
-
Oncology Drug Approval News Flash: Datopotamab Deruxtecan-dlnk (Datroway) Approved by FDA for HR-Positive, HER2-Negative Breast Cancer
【FDA Approval Alert】Daiichi Sankyo's Datroway Approved for HR-Positive, HER2-Negative Breast Cancer (January 17, 2025) On January 17, 2025, the U.S. FDA approved datopotamab deruxtecan-dlnk (Datroway) for adults with unresectable or me... -
2025 Therapeutics Trend
What are the trends in therapeutics and market launch drugs in 2025? Market Expansion and Contested Competition for Obesity Drugs ADC Wave and Next Generation ADC (Antibody Drug Conjugate) Challenges for Rare Disease Therapeutic Roles an...
